To outcompete China, unhandcuff America’s biotech innovators
Former official David Mansdoerfer argues that bureaucratic delays at the FDA threaten American leadership in the growing regenerative medicine sector and give international competitors like China a strategic advantage.
Former official David Mansdoerfer argues that bureaucratic delays at the FDA threaten American leadership in the growing regenerative medicine sector and give international competitors like China a strategic advantage.
This article was originally published at: https://thehill.com/opinion/healthcare/6040418-fda-regula...